The estimated Net Worth of John P Gandolfo is at least $682 ezer dollars as of 13 June 2024. Mr. Gandolfo owns over 1,000 units of Eyenovia Inc stock worth over $28,394 and over the last 7 years he sold EYEN stock worth over $0. In addition, he makes $653,635 as Chief Financial Officer és Secretary at Eyenovia Inc.
John has made over 6 trades of the Eyenovia Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of EYEN stock worth $6,430 on 13 June 2024.
The largest trade he's ever made was buying 15,000 units of Eyenovia Inc stock on 17 May 2022 worth over $5,400. On average, John trades about 1,400 units every 109 days since 2018. As of 13 June 2024 he still owns at least 50,704 units of Eyenovia Inc stock.
You can see the complete history of Mr. Gandolfo stock trades at the bottom of the page.
John P. Gandolfo serves as Chief Financial Officer, Secretary of the Company. Mr. Gandolfo has approximately 30 years of experience as a chief financial officer of multiple rapidly growing private and publicly held companies with a primary focus in the life sciences, healthcare and medical device areas. Mr. Gandolfo has had direct responsibility over capital raising, including five public offerings, financial management, mergers and acquisition transactions and SEC reporting throughout his professional career. Prior to joining Eyenovia, Mr. Gandolfo was Chief Financial Officer of Xtant Medical Holdings, Inc. (NYSE: XTNT) from July 2010 through September 2017. Prior to joining Xtant, he served as the Chief Financial Officer for Progenitor Cell Therapy LLC, the global contract development and manufacturing services platform of the Hitachi Chemical Regenerative Medicine Business Sector, represented in the United States by Hitachi Chemical Advanced Therapeutics Solutions, LLC, a manufacturer of stem cell therapies, from January 2009 to June 2010. Prior to joining Progenitor, Mr. Gandolfo served as the Chief Financial Officer of Power Medical Interventions, Inc. (acquired by Covidien Public Limited Company (NYSE: COV, which was in turn acquired by Medtronic Public Limited Company (NYSE: MDT)), a publicly held developer and manufacturer of computerized surgical stapling and cutter systems, from January 2007 to January 2009. Prior to joining Power Medical Interventions, Mr. Gandolfo was the Chief Financial Officer of Bioject Medical Technologies, Inc., a then publicly held supplier of needle-free drug delivery systems to the pharmaceutical and biotechnology industries, from September 2001 to May 2006, and served on the Bioject’s board of directors from September 2006 through May 2007.
As the Chief Financial Officer és Secretary of Eyenovia Inc, the total compensation of John Gandolfo at Eyenovia Inc is $653,635. There are 2 executives at Eyenovia Inc getting paid more, with Tsontcho Ianchulev having the highest compensation of $1,247,140.
John Gandolfo is 59, he's been the Chief Financial Officer és Secretary of Eyenovia Inc since 2017. There are 6 older and 5 younger executives at Eyenovia Inc. The oldest executive at Eyenovia Inc is Ernest Mario, 81, who is the Independent Director.
John's mailing address filed with the SEC is 200 FORGE WAY, SUITE 205, , ROCKAWAY, NJ, 07866.
Over the last 7 years, insiders at Eyenovia Inc have traded over $1,275,000 worth of Eyenovia Inc stock and bought 6,072,235 units worth $17,599,075 . The most active insiders traders include Ernest Mario, Stuart M. Grant és Fredric N Eshelman. On average, Eyenovia Inc executives and independent directors trade stock every 31 days with the average trade being worth of $49,678. The most recent stock trade was executed by Michael M Rowe on 28 August 2024, trading 27,071 units of EYEN stock currently worth $14,077.
eyenovia, inc. (nasdaq: eyen) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, presbyopia, mydriasis and other eye diseases.
Eyenovia Inc executives and other stock owners filed with the SEC include: